Published in Reg Anesth Pain Med on July 03, 2009
Does lack of anesthetic assistance justify a suboptimal ultrasound-guided regional anesthetic technique? Reg Anesth Pain Med (2010) 0.75
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev (2004) 2.72
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev (2004) 2.35
Mechanisms of bone repair and regeneration. Trends Mol Med (2009) 1.61
Adhesion and osteogenic differentiation of human mesenchymal stem cells on titanium nanopores. Eur Cell Mater (2011) 1.52
The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J Biol Chem (2013) 1.49
Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) (2013) 1.42
Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells. Plast Reconstr Surg (2016) 1.40
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol (2003) 1.38
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer (2005) 1.30
Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells (2012) 1.29
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res (2007) 1.26
Ectopic bone formation by microporous calcium phosphate ceramic particles in sheep muscles. Bone (2005) 1.25
Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders. Cytokine Growth Factor Rev (2002) 1.24
Human cytomegalovirus entry into dendritic cells occurs via a macropinocytosis-like pathway in a pH-independent and cholesterol-dependent manner. PLoS One (2012) 1.14
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res (2010) 1.12
Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol (2010) 1.11
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res (2010) 1.10
Proteoglycans: key partners in bone cell biology. Bioessays (2007) 1.07
Concise review: embryonic stem cells: a new tool to study osteoblast and osteoclast differentiation. Stem Cells (2006) 1.07
Differential dependence on Beclin 1 for the regulation of pro-survival autophagy by Bcl-2 and Bcl-xL in HCT116 colorectal cancer cells. PLoS One (2010) 1.06
Novel biomaterials for bisphosphonate delivery. Biomaterials (2005) 1.04
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer (2006) 1.04
OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone (2006) 1.02
Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev (2013) 1.02
Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res (2009) 1.01
Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One (2010) 1.01
Micro-architecture of calcium phosphate granules and fibrin glue composites for bone tissue engineering. Biomaterials (2005) 1.00
Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med (2009) 1.00
Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells. PLoS One (2012) 0.98
Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res (2004) 0.98
Oxytocin reverses ovariectomy-induced osteopenia and body fat gain. Endocrinology (2014) 0.96
Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis (2011) 0.96
Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy (2014) 0.96
Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep (2007) 0.96
Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res (2010) 0.96
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol (2006) 0.95
The safety and efficacy of an injectable bone substitute in dental sockets demonstrated in a human clinical trial. Biomaterials (2007) 0.94
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther (2009) 0.94
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer (2014) 0.94
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer (2014) 0.94
Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine (2010) 0.93
Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res (2008) 0.91
First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mTc-NTP 15-5 radiotracer. J Nucl Med (2009) 0.90
Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoid body. In Vitro Cell Dev Biol Anim (2007) 0.90
Behaviour of mesenchymal stem cells, fibroblasts and osteoblasts on smooth surfaces. Acta Biomater (2010) 0.90
Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother (2011) 0.89
Osteogenic properties of calcium phosphate ceramics and fibrin glue based composites. J Mater Sci Mater Med (2007) 0.89
Proteoglycans on bone tumor development. Drug Discov Today (2010) 0.89
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. Curr Med Chem (2007) 0.89
Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther (2008) 0.89
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am J Cancer Res (2011) 0.88
Distinct roles of Bcl-2 and Bcl-Xl in the apoptosis of human bone marrow mesenchymal stem cells during differentiation. PLoS One (2011) 0.88
Bone tissue formation in sheep muscles induced by a biphasic calcium phosphate ceramic and fibrin glue composite. J Mater Sci Mater Med (2007) 0.88
Cell-specific effects of TNF-α and IL-1β on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. Lab Invest (2011) 0.87
Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol Rep (2006) 0.87
RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol (2008) 0.87
Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J Biol Chem (2009) 0.86
Molecular alterations associated with osteosarcoma development. Sarcoma (2012) 0.86
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res (2011) 0.86
TRAIL-based therapy in pediatric bone tumors: how to overcome resistance. Future Oncol (2015) 0.86
Calcium phosphate scaffold and bone marrow for bone reconstruction in irradiated area: a dog study. Bone (2005) 0.85
Mechanistic study of the proangiogenic effect of osteoprotegerin. Angiogenesis (2013) 0.85
Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-κB ligand (RANK)-L by rat plasmacytoid dendritic cells. PLoS One (2012) 0.85
Alveolar bone regeneration for immediate implant placement using an injectable bone substitute: an experimental study in dogs. J Periodontol (2004) 0.84
MBCP biphasic calcium phosphate granules and tissucol fibrin sealant in rabbit femoral defects: the effect of fibrin on bone ingrowth. J Mater Sci Mater Med (2005) 0.84
Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. Cytokine (2012) 0.84
Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient. J Bone Miner Res (2011) 0.84
Direct anti-cancer effect of oncostatin M on chondrosarcoma. Int J Cancer (2011) 0.84
Physico-chemical-mechanical and in vitro biological properties of calcium phosphate cements with doped amorphous calcium phosphates. Biomaterials (2006) 0.84
Mesomelia-synostoses syndrome results from deletion of SULF1 and SLCO5A1 genes at 8q13. Am J Hum Genet (2010) 0.84
Pomegranate seed oil prevents bone loss in a mice model of osteoporosis, through osteoblastic stimulation, osteoclastic inhibition and decreased inflammatory status. J Nutr Biochem (2013) 0.84
Pomegranate and its derivatives can improve bone health through decreased inflammation and oxidative stress in an animal model of postmenopausal osteoporosis. Eur J Nutr (2014) 0.83
Mice with hypomorphic expression of the sodium-phosphate cotransporter PiT1/Slc20a1 have an unexpected normal bone mineralization. PLoS One (2013) 0.83
Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration. BMC Cancer (2014) 0.83
In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite. Biomaterials (2010) 0.83
Hamstring insertion site healing after anterior cruciate ligament reconstruction in patients with symptomatic hardware or repeat rupture: a histologic study in 12 patients. Arthroscopy (2003) 0.83
Oncostatin M is a growth factor for Ewing sarcoma. Am J Pathol (2012) 0.83
Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue. FASEB J (2013) 0.83
Modulatory effects of proteoglycans on proteinase activities. Methods Mol Biol (2012) 0.83
Drug-eluting stents in bifurcations: bench study of strut deformation and coating lesions. Circ Cardiovasc Interv (2010) 0.83
Combined spinal cord monitoring using neurogenic mixed evoked potentials and collision techniques. Spine (Phila Pa 1976) (2002) 0.83
Size dependent bioaccumulation and ecotoxicity of gold nanoparticles in an endobenthic invertebrate: the Tellinid clam Scrobicularia plana. Environ Pollut (2012) 0.82
In vitro biological effects of titanium rough surface obtained by calcium phosphate grid blasting. Biomaterials (2005) 0.82
The involvement of SMILE/TMTC3 in endoplasmic reticulum stress response. PLoS One (2011) 0.82
New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance. Lab Invest (2013) 0.82
Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone (2009) 0.82
A comparison between bone reconstruction following the use of mesenchymal stem cells and total bone marrow in association with calcium phosphate scaffold in irradiated bone. Biomaterials (2008) 0.82
Hybrid composites of calcium phosphate granules, fibrin glue, and bone marrow for skeletal repair. J Biomed Mater Res A (2007) 0.81
Osteoclasts in RA: diverse origins and functions. Joint Bone Spine (2013) 0.81
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther (2008) 0.81
Osteoprotegerin: a new therapeutic agent for the treatment of bone disease. Drug Discov Today (2001) 0.81
Bone repair using a new injectable self-crosslinkable bone substitute. J Orthop Res (2006) 0.81
The vertebral interbody grafting site's low concentration in osteogenic progenitors can greatly benefit from addition of iliac crest bone marrow. Eur Spine J (2005) 0.80
Ultrasound imaging of the sciatic nerve in the lateral midfemoral approach. Reg Anesth Pain Med (2009) 0.80
Computed tomography scanning of the sciatic nerve posterior to the femur: Practical implications for the lateral midfemoral block. Reg Anesth Pain Med (2003) 0.80
Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. Eur J Cell Biol (2010) 0.79